Alejandro A. Inclan

Oncology
4724 N Davis Hwy
Pensacola, FL 32503

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial.

Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial.

Journal: Breast cancer research and treatment
Published: August 13, 2014
Showing 1-1 of 1

Last Updated: 09/26/2026